Helena Benlloch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helena Benlloch has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anna Esteve-Codina
Centro Nacional de Analisis Genomico (CNAG)
1 shared publication - Dmytro Kukhtar
IDIBELL
1 shared publication - Eric Cornes
Mechanisms of Epigenetic Inheritance, Department of Developmental and Stem Cell Biology, Institut Pasteur, UMR3738, CNRS, Paris, France
1 shared publication - Germano Cecere
Mechanisms of Epigenetic Inheritance Unit, Department of Developmental and Stem Cell Biology, Institut Pasteur, CNRS UMR3738, Université Paris Cité, Paris, France
1 shared publication - Julián Cerón
Modeling Human Diseases in C. elegans - Genes, Disease and Therapy Program, Bellvitge Biomedical Research Institute -IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
1 shared publication - Xènia Serrat
Affiliation The Donnelly Centre, University of Toronto, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 21 October 2019
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 15 (10) , e1008464
CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing
SF3B1 is the most frequently mutated splicing factor in cancer. Mutations in SF3B1 likely confer clonal advantages to cancer cells but they may also confer vulnerabilities that can be therapeutically targeted. SF3B1 cancer mutations can be maintained in homozygosis in C. elegans, allowing synthetic lethal screens with a homogeneous population of animals. These mutations cause alternative splicing (AS) defects in C. elegans, as it occurs in SF3B1-mutated human cells. In a screen, we identified RNAi of U2 snRNP components that cause synthetic lethality with sftb-1/SF3B1 mutations. We also detected synthetic interactions between sftb-1 mutants and cancer-related mutations in uaf-2/U2AF1 or rsp-4/SRSF2, demonstrating that this model can identify interactions between mutations that are mutually exclusive in human tumors. Finally, we have edited an SFTB-1 domain to sensitize C. elegans to the splicing modulators pladienolide B or herboxidiene. Thus, we have established a multicellular model for SF3B1 mutations amenable for high-throughput genetic and chemical screens. SF3B1 encodes a splicing factor frequently mutated in hematological malignancies, and with less frequency in other solid tumors. Each SF3B1 mutation is predominant in a cancer type, indicating cell type-specific pathogenic mechanisms. We have reproduced three cancer-related SF3B1 missense mutations in the C. elegans ortholog sftb-1 and they do not cause any overt phenotypes, but few alterations in splicing. However, the combination of these mutations has additive effects, hampering SFTB-1 functions and allowing the study of synthetic interactions that may result in a defective spliceosome structure. As a result of an RNAi screen, we identified other proteins of the U2 snRNP complex as targets for synthetic lethality. The sftb-1 mutant strains also allow the identification of mutations in other splicing factors that are mutually exclusive with SF3B1 mutations in tumors. SF3B1 cancer mutations are heterozygous, and interestingly, the most promising therapeutic venue is based on pladienolide B (PB) derivatives that hit the wild-type and the mutated protein. We have edited SFTB-1 to sensitize it to pladienolide B (PB) and herboxidiene (HB), therefore making C. elegans suitable for assaying the toxicity and efficacy of their chemical derivatives. Thus, our model represents a pre-clinical system to investigate both synthetic lethality and chemotherapies. Besides that, we have generated the first C. elegans strain in which splicing can be chemically modulated by PB and HB.
- 21 October 2019
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 15 (10) , e1008464
Open AccessCRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing
SF3B1 is the most frequently mutated splicing factor in cancer. Mutations in SF3B1 likely confer clonal advantages to cancer cells but they may also confer vulnerabilities that can be therapeutically targeted. SF3B1 cancer mutations can be maintained in homozygosis in C. elegans, allowing synthetic lethal screens with a homogeneous population of animals. These mutations cause alternative splicing (AS) defects in C. elegans, as it occurs in SF3B1-mutated human cells. In a screen, we identified RNAi of U2 snRNP components that cause synthetic lethality with sftb-1/SF3B1 mutations. We also detected synthetic interactions between sftb-1 mutants and cancer-related mutations in uaf-2/U2AF1 or rsp-4/SRSF2, demonstrating that this model can identify interactions between mutations that are mutually exclusive in human tumors. Finally, we have edited an SFTB-1 domain to sensitize C. elegans to the splicing modulators pladienolide B or herboxidiene. Thus, we have established a multicellular model for SF3B1 mutations amenable for high-throughput genetic and chemical screens. SF3B1 encodes a splicing factor frequently mutated in hematological malignancies, and with less frequency in other solid tumors. Each SF3B1 mutation is predominant in a cancer type, indicating cell type-specific pathogenic mechanisms. We have reproduced three cancer-related SF3B1 missense mutations in the C. elegans ortholog sftb-1 and they do not cause any overt phenotypes, but few alterations in splicing. However, the combination of these mutations has additive effects, hampering SFTB-1 functions and allowing the study of synthetic interactions that may result in a defective spliceosome structure. As a result of an RNAi screen, we identified other proteins of the U2 snRNP complex as targets for synthetic lethality. The sftb-1 mutant strains also allow the identification of mutations in other splicing factors that are mutually exclusive with SF3B1 mutations in tumors. SF3B1 cancer mutations are heterozygous, and interestingly, the most promising therapeutic venue is based on pladienolide B (PB) derivatives that hit the wild-type and the mutated protein. We have edited SFTB-1 to sensitize it to pladienolide B (PB) and herboxidiene (HB), therefore making C. elegans suitable for assaying the toxicity and efficacy of their chemical derivatives. Thus, our model represents a pre-clinical system to investigate both synthetic lethality and chemotherapies. Besides that, we have generated the first C. elegans strain in which splicing can be chemically modulated by PB and HB.